Table 1 Characteristics of selected trials
From: A review of new hormonal therapies for prostate cancer in black men: is there enough data?
Trial (NCT) | Study design | Level of evidence | Treatment | Population | Number of patients (N) | Median age | Baseline PSA | Gleason grade groups | PS |
|---|---|---|---|---|---|---|---|---|---|
Tsao et al. 2016 | Ph. II prospective study | 2c | Abiraterone | mCRPC black men | 11 | 66 | NR | NR | OMS 0 73% OMS 1 27% |
Ryan et al. 2018 | Ph. II prospective study | 2c | Abiraterone | M0 CRPC | 19 | NR | NR | NR | NR |
Ramalingam et al. 2017 [14] | Retrospective comparative case-control study | 4 | Abiraterone | mCRPC black men | 45 | NR | NR | Gr. 1–3 42% Gr. 4–5 58% | OMS 0 92% OMS 1 8% |
Leuva et al. 2019 [15] | Retrospective cohort study | 2b | Abiraterone and Enzalutamide | mCRPC black men | 1116 | 73–78 | 45.8–48.7 | NR | NR |